Stamulumab
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research[1][2].
Product Specifications
CAS Number
705287-60-1
Product Name Alternative
MYO-029
UNSPSC
12352203
Target
TGF-β Receptor
Type
Inhibitory Antibodies
Related Pathways
TGF-beta/Smad
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/stamulumab.html
Purity
95.07
Solubility
H2O
Smiles
[Stamulumab]
Molecular Weight
(142.56 kDa)
References & Citations
[1]P Singh, et al. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Clin Transl Sci. 2016 Dec;9 (6) :302-310.|[2]Kathryn R Wagner, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May;63 (5) :561-71.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TL704358V 500 µL Each
Tnfrsf17 Rat shRNA Lentiviral Particle (Locus ID 287034)
Sign In for Pricing
View Details 
MBS6148826-01 0.1 mL
PHKA2 (Phosphorylase B Kinase Regulatory Subunit alpha, Liver Isoform, Phosphorylase Kinase alpha L Subunit, PHKLA, PYK, MGC133071) (FITC)
Sign In for Pricing
View Details MBS6148826-02 5x 0.1 mL
PHKA2 (Phosphorylase B Kinase Regulatory Subunit alpha, Liver Isoform, Phosphorylase Kinase alpha L Subunit, PHKLA, PYK, MGC133071) (FITC)
Sign In for Pricing
View Details 